12 completed, 3 terminated, 2 active not recruiting, 2 recruiting. 21 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 21 | Completed 12, Terminated 3, Active not recruiting 2, Recruiting 2, Unknown 1, Withdrawn 1 |
| Phase 2 | 3 | Terminated 2, Completed 1 |
Follow Peripheral Nervous System Neoplasms: new trials by email Literature Review of Peripheral Nervous System Neoplasms trials Research Report on Peripheral Nervous System Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas TQ-B3234 capsules, TQ-B3234 placebo - Plexiform Neurofibroma | Phase 3 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 177 | 2026-03-31 | 2026-05-27 |
| Steroids for Facial Nerve Function Protection in Post-surgical Vestibular Schwannoma Patients Steroids therapy, Placebo - Vestibular Schwannoma, Facial Nerve Paralysis | Phase 3 | Recruiting | Beijing Tiantan Hospital | 364 | 2025-10-09 | 2026-10-26 |
| FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas Test group (Group A): FCN-159 8 mg, orally, once daily;, Control group (Group B): Placebo, orally, once daily; - Neurofibromatosis 1, Plexiform Neurofibroma | Phase 3 | Active not recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 167 | 2023-06-20 | 2025-03-06 |
| Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas Selumetinib, Placebo - Neurofibromatosis 1, Plexiform Neurofibroma (PN) | Phase 3 | Active not recruiting | AstraZeneca | 145 | 2021-11-19 | 2026-03-23 |
| Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain Acceptance and Commitment Therapy (ACT) - Neurofibromatosis Type 1, Plexiform Neurofibromas | Phase 3 | Completed | National Cancer Institute (NCI) | 66 | 2015-07-07 | 2022-06-14 |
| Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide - Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 140 | 2014-08-12 | 2026-06-17 |
| Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma Temozolomide, ANP Therapy - Optic Nerve Glioma | Phase 3 | Withdrawn | Burzynski Research Institute | 2011-12-01 | 2017-07-26 | |
| Stereotactic Radiation in Vestibular Schwannoma stereotactic radiotherapy, stereotactic radiosurgery - Vestibular Schwannoma | Phase 3 | Unknown | Ramathibodi Hospital | 200 | 2011-10-01 | 2011-10-10 |
| Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma doxorubicin hydrochloride, trabectedin, laboratory biomarker analysis - Sarcoma | Phase 2 / Phase 3 | Terminated | European Organisation for Research and Treatment of Cancer - EORTC | 133 | 2011-05-01 | 2014-08-08 |
| Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer cyproheptadine hydrochloride, placebo - Cancer | Phase 3 | Terminated | University of South Florida | 22 | 2010-06-01 | 2015-07-02 |
| Corticosteroids in Prevention of Facial Palsy After Cranial Base Surgery methylprednisolone - Facial Palsy | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 313 | 2007-03-01 | 2012-07-10 |
| Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma doxorubicin hydrochloride, clinical observation, therapeutic conventional surgery - Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma | Phase 3 | Completed | Children's Oncology Group | 588 | 2007-02-05 | 2022-04-28 |
| Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors imatinib mesylate - Malignant Peripheral Nerve Sheath Tumors | Phase 2 / Phase 3 | Terminated | Novartis Pharmaceuticals | 11 | 2006-05-01 | 2012-08-07 |
| Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma radiotherapy - Sarcoma | Phase 3 | Completed | Sheffield Teaching Hospitals NHS Foundation Trust | 216 | 2006-03-01 | 2021-03-18 |
| Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis conventional surgery, radiation therapy - Sarcoma | Phase 3 | Completed | Alliance for Clinical Trials in Oncology | 370 | 2004-08-01 | 2016-07-06 |
| Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma pegfilgrastim, doxorubicin hydrochloride, ifosfamide - Sarcoma | Phase 3 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 455 | 2003-04-01 | 2014-10-27 |
| Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma doxorubicin hydrochloride, ifosfamide - Sarcoma | Phase 3 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 780 | 1998-01-01 | 2012-01-20 |
| Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma doxorubicin hydrochloride, etoposide, ifosfamide - Sarcoma | Phase 3 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 340 | 1997-07-01 | 2013-09-17 |
| Combination Chemotherapy in Treating Children With Progressive Brain Tumors carboplatin, lomustine, procarbazine hydrochloride - Brain Tumors, Central Nervous System Tumors | Phase 3 | Completed | Children's Oncology Group | 428 | 1997-04-01 | 2013-09-09 |
| Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma filgrastim, doxorubicin hydrochloride, ifosfamide - Endometrial Cancer, Kidney Cancer | Phase 3 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 340 | 1996-04-01 | 2012-07-11 |
Showing 20 of 21. Sign in to see all of them.
Fibrosarcoma (11) · Neurofibrosarcoma (11) · Sarcoma (11) · Hemangiosarcoma (10) · Histiocytoma, Malignant Fibrous (10) · Leiomyosarcoma (10) · Liposarcoma (10) · Sarcoma, Synovial (10) · Hemangiopericytoma, Malignant (6) · Sarcoma, Alveolar Soft Part (6) · Malignant mesenchymal tumor (5) · Chondrosarcoma, Extraskeletal Myxoid (4) · Neurofibroma, Plexiform (4) · Rhabdomyosarcoma (4) · Neurofibromatosis 1 (3)
Neoplasms by Histologic Type (21) · Neoplasms, Nerve Tissue (21) · Nervous System Diseases (21) · Nervous System Neoplasms (21) · Neoplasms (20) · Nerve Sheath Neoplasms (16) · Neurofibroma (15) · Neuromuscular Diseases (15) · Peripheral Nervous System Diseases (15) · Neoplasms, Connective Tissue (12) · Neoplasms, Connective and Soft Tissue (12) · Neoplasms, Fibrous Tissue (12) · Histiocytoma (10) · Neoplasms, Adipose Tissue (10)
Doxorubicin (8) · Ifosfamide (7) · Radiotherapy (5) · Filgrastim (2) · AZD 6244 (1) · Acceptance and Commitment Therapy (1) · Carboplatin (1) · Chemotherapy, Adjuvant (1) · Combined Modality Therapy (1) · Control Groups (1) · Cyproheptadine (1) · Diathermy (1) · Etoposide (1) · Imatinib Mesylate (1) · Lomustine (1)
European Organisation for Research and Treatment of Cancer - EORTC (6) · Children's Oncology Group (2) · National Cancer Institute (NCI) (2) · Alliance for Clinical Trials in Oncology (1) · Assistance Publique - Hôpitaux de Paris (1) · AstraZeneca (1) · Beijing Tiantan Hospital (1) · Burzynski Research Institute (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Novartis Pharmaceuticals (1) · Ramathibodi Hospital (1) · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (1) · Sheffield Teaching Hospitals NHS Foundation Trust (1) · University of South Florida (1)
United States (8) · Canada (7) · Germany (7) · France (6) · United Kingdom (6) · Netherlands (5) · Spain (5) · Belgium (4) · China (4) · Denmark (4) · Slovakia (4) · Switzerland (4) · Australia (3) · Austria (3) · Poland (3)
A.N. Van Geel, MD (1) · Aaron R Weiss (1) · Alice P. Chen, MD (1) · Ian R. Judson, MA, MD, FRCP (1) · James E. Butrynski, MD (1) · Jeffrey P. Krischer, PhD (1) · Joann Ater, MD (1) · Laurence H. Baker, DO, FACOI (1) · Martin Robinson, MD (1) · Nguyen Binh Bui, MD (1) · Paul C. Lorigan, MD (1) · Penella J. Woll, MD, PhD (1) · Peter Pisters, MD (1)
PMID 17634494, PMID 20434400, PMID 22665535, PMID 22954508, PMID 24618336, PMID 24747207, PMID 28391003, PMID 29450452, PMID 30954717, PMID 31786124, PMID 32702309, PMID 32827353, PMID 33548339, PMID 34515544, PMID 34623899, PMID 34666214, PMID 36566574, PMID 37523624, PMID 38757485, PMID 39122389, PMID 40473450, PMID 41386267, PMID 42035475
U10CA098543 (2), 2009 (1), U10CA081920 (1), U10CA180830 (1), U10CA180886 (1)